Current immunotherapeutic agents under investigation have the potential to significantly expand our ability to effectively treat B-cell malignancies. New disease targets, novel strategies to deliver therapy, and advanced agents that work to manipulate the immune system are a few of the ways immunotherapy has quickly evolved. Novel targeted and immune-modifying therapies may demonstrate early potential but unique toxicities and other limitations, such as difficulties in administration, must also be acknowledged. This review provides a comprehensive assessment of the current immunotherapies under investigation against B-cell malignancies.